Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ: HCM )

14.31 -0.30 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee 
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2023 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
From HUTCHMED (China) Limited
Via GlobeNewswire
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
10 Stocks Reacting To April PCE: Marvell Technology Leads The Rally
Via Benzinga
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces Board of Directors and Board Committee Membership
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
Intended Retirement of Independent Non-executive Director
From HUTCHMED (China) Limited
Via GlobeNewswire
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Liquid Media Group Ltd. (NASDAQ: YVR) jumped 88.1% to $0.2719. 
Via Benzinga
Lamb Weston, TH International, AMC Entertainment And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43. 
Via Benzinga
Why Is HUTCHMED Stock Trading Higher Today?
HUTCHMED (China) Limited (NASDAQ: HCM) shares are trading higher on Tuesday after the company initiated enrollment registration for its ongoing Phase 2 trial of HMPL-453 for intrahepatic... 
Via Benzinga
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.